# A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Source: https://onco.cc/trials/nct05944224/  
OnCo record `nct05944224` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SPH4336 and Cadonilimab in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.

## Summary

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05944224 by Shanghai Pharmaceuticals Holding Co., Ltd, with 63 participants planned, started 2023-10-17 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH4336 and Cadonilimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05944224
- Phase: 1/2
- Setting: A Randomized, Open-label, Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors, Including Advanced Well Differentiated/Dedifferentiated Liposarcoma.
- Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT05944224: https://clinicaltrials.gov/study/NCT05944224

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [SPH4336](https://onco.cc/drugs/sph4336/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)

---
JSON: https://onco.cc/api/v1/entities/nct05944224.json